Archeus Technologies, WARF launching clinical trial this year for cancer targeting molecule
Home » Uncategorized » Archeus Technologies, WARF launching clinical trial this year for cancer targeting molecule
Archeus Technologies in Madison and WARF are launching a clinical trial this year for a targeting molecule used in treating prostate cancer.
The organizations yesterday announced the plans to further develop ART-101, a receptor-based targeting molecule developed at UW-Madison’s Advanced Radiotheranostics lab. It’s designed to deliver radioactive isotopes within the body as part of a targeted trea...
Please log in to access subscriber content.
If you don't have a subscription, please contact schmies@wispolitics.com for subscription options on the WisPolitics-State Affairs platform, which is the new home for WisPolitics subscriber products.
